Skip to content

Spanish study shows the benefits of starting HIV treatment at higher CD4 cell counts

CROI: Kivexa and Truvada have similar efficacy and safety

CROI: Region of origin and gender significant in long-term changes in CD4 cell count during effective HIV therapy

CROI: Untreated HIV-positive individuals have a higher risk of death even at CD4 counts over 350

CROI: Delaying HAART while treating opportunistic infections increases the risk of disease progression and death

CROI: Could earlier ART reduce risk of death from non-AIDS related illnesses in people with HIV?

CROI: Once-daily boosted atazanavir comparable to twice-daily Kaletra in treatment-naive patients, with better lipid profile

Patients who start anti-HIV treatment with a low CD4 cell count have a good chance of an undetectable viral load

Factors affecting HIV therapy choice in women have changed